<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang xml:lang>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Your Digest for Friday, Dec 15, 2023 03:59 PM</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
  </style>
  <style type="text/css">
:root,
::backdrop {

--sans-font: -apple-system, BlinkMacSystemFont, "Avenir Next", Avenir,
"Nimbus Sans L", Roboto, "Noto Sans", "Segoe UI", Arial, Helvetica,
"Helvetica Neue", sans-serif;
--mono-font: Consolas, Menlo, Monaco, "Andale Mono", "Ubuntu Mono", monospace;
--standard-border-radius: 5px;

--bg: #fff;
--accent-bg: #f5f7ff;
--text: #212121;
--text-light: #585858;
--border: #898EA4;
--accent: #0d47a1;
--code: #d81b60;
--preformatted: #444;
--marked: #ffdd33;
--disabled: #efefef;
}

@media (prefers-color-scheme: dark) {
:root,
::backdrop {
color-scheme: dark;
--bg: #212121;
--accent-bg: #2b2b2b;
--text: #dcdcdc;
--text-light: #ababab;
--accent: #ffb300;
--code: #f06292;
--preformatted: #ccc;
--disabled: #111;
}

img,
video {
opacity: 0.8;
}
}

*, *::before, *::after {
box-sizing: border-box;
}

textarea,
select,
input,
progress {
appearance: none;
-webkit-appearance: none;
-moz-appearance: none;
}
html {

font-family: var(--sans-font);
scroll-behavior: smooth;
}

body {
color: var(--text);
background-color: var(--bg);
font-size: 1.15rem;
line-height: 1.5;
display: grid;
grid-template-columns: 1fr min(45rem, 90%) 1fr;
margin: 0;
}
body > * {
grid-column: 2;
}

body > header {
background-color: var(--accent-bg);
border-bottom: 1px solid var(--border);
text-align: center;
padding: 0 0.5rem 2rem 0.5rem;
grid-column: 1 / -1;
}
body > header h1 {
max-width: 1200px;
margin: 1rem auto;
}
body > header p {
max-width: 40rem;
margin: 1rem auto;
}

main {
padding-top: 1.5rem;
}
body > footer {
margin-top: 4rem;
padding: 2rem 1rem 1.5rem 1rem;
color: var(--text-light);
font-size: 0.9rem;
text-align: center;
border-top: 1px solid var(--border);
}

h1 {
font-size: 3rem;
}
h2 {
font-size: 2.6rem;
margin-top: 3rem;
}
h3 {
font-size: 2rem;
margin-top: 3rem;
}
h4 {
font-size: 1.44rem;
}
h5 {
font-size: 1.15rem;
}
h6 {
font-size: 0.96rem;
}

p, h1, h2, h3, h4, h5, h6 {
overflow-wrap: break-word;
}

h1,
h2,
h3 {
line-height: 1.1;
}

@media only screen and (max-width: 720px) {
h1 {
font-size: 2.5rem;
}
h2 {
font-size: 2.1rem;
}
h3 {
font-size: 1.75rem;
}
h4 {
font-size: 1.25rem;
}
}

a,
a:visited {
color: var(--accent);
}
a:hover {
text-decoration: none;
}
button,
.button,
a.button, 
input[type="submit"],
input[type="reset"],
input[type="button"],
label[type="button"] {
border: none;
border-radius: var(--standard-border-radius);
background-color: var(--accent);
font-size: 1rem;
color: var(--bg);
padding: 0.7rem 0.9rem;
margin: 0.5rem 0;
text-decoration: none;
font-family: inherit;
line-height: normal;
}
.button[aria-disabled="true"], input:disabled,
textarea:disabled,
select:disabled,
button[disabled] {
cursor: not-allowed;
background-color: var(--disabled);
color: var(--text-light)
}
input[type="range"] {
padding: 0;
}

abbr[title] {
cursor: help;
text-decoration-line: underline;
text-decoration-style: dotted;
}
button:enabled:hover,
.button:not([aria-disabled="true"]):hover,
input[type="submit"]:enabled:hover,
input[type="reset"]:enabled:hover,
input[type="button"]:enabled:hover,
label[type="button"]:hover {
filter: brightness(1.4);
cursor: pointer;
}
.button:focus-visible,
button:focus-visible:where(:enabled),
input:enabled:focus-visible:where(
[type="submit"],
[type="reset"],
[type="button"]
) {
outline: 2px solid var(--accent);
outline-offset: 1px;
}

header > nav {
font-size: 1rem;
line-height: 2;
padding: 1rem 0 0 0;
}

header > nav ul,
header > nav ol {
align-content: space-around;
align-items: center;
display: flex;
flex-direction: row;
flex-wrap: wrap;
justify-content: center;
list-style-type: none;
margin: 0;
padding: 0;
}

header > nav ul li,
header > nav ol li {
display: inline-block;
}
header > nav a,
header > nav a:visited {
margin: 0 0.5rem 1rem 0.5rem;
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
color: var(--text);
display: inline-block;
padding: 0.1rem 1rem;
text-decoration: none;
}
header > nav a:hover,
header > nav a.current,
header > nav a[aria-current="page"] {
border-color: var(--accent);
color: var(--accent);
cursor: pointer;
}

@media only screen and (max-width: 720px) {
header > nav a {
border: none;
padding: 0;
text-decoration: underline;
line-height: 1;
}
}

aside, details, pre, progress {
background-color: var(--accent-bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
aside {
font-size: 1rem;
width: 30%;
padding: 0 15px;
margin-inline-start: 15px;
float: right;
}
*[dir="rtl"] aside {
float: left;
}

@media only screen and (max-width: 720px) {
aside {
width: 100%;
float: none;
margin-inline-start: 0;
}
}
article, fieldset, dialog {
border: 1px solid var(--border);
padding: 1rem;
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
article h2:first-child,
section h2:first-child {
margin-top: 1rem;
}
section {
border-top: 1px solid var(--border);
border-bottom: 1px solid var(--border);
padding: 2rem 1rem;
margin: 3rem 0;
}

section + section,
section:first-child {
border-top: 0;
padding-top: 0;
}
section:last-child {
border-bottom: 0;
padding-bottom: 0;
}
details {
padding: 0.7rem 1rem;
}
summary {
cursor: pointer;
font-weight: bold;
padding: 0.7rem 1rem;
margin: -0.7rem -1rem;
word-break: break-all;
}
details[open] > summary + * {
margin-top: 0;
}
details[open] > summary {
margin-bottom: 0.5rem;
}
details[open] > :last-child {
margin-bottom: 0;
}

table {
border-collapse: collapse;
margin: 1.5rem 0;
}
td,
th {
border: 1px solid var(--border);
text-align: start;
padding: 0.5rem;
}
th {
background-color: var(--accent-bg);
font-weight: bold;
}
tr:nth-child(even) {

background-color: var(--accent-bg);
}
table caption {
font-weight: bold;
margin-bottom: 0.5rem;
}

textarea,
select,
input {
font-size: inherit;
font-family: inherit;
padding: 0.5rem;
margin-bottom: 0.5rem;
color: var(--text);
background-color: var(--bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
box-shadow: none;
max-width: 100%;
display: inline-block;
}
label {
display: block;
}
textarea:not([cols]) {
width: 100%;
}

select:not([multiple]) {
background-image: linear-gradient(45deg, transparent 49%, var(--text) 51%),
linear-gradient(135deg, var(--text) 51%, transparent 49%);
background-position: calc(100% - 15px), calc(100% - 10px);
background-size: 5px 5px, 5px 5px;
background-repeat: no-repeat;
padding-inline-end: 25px;
}
*[dir="rtl"] select:not([multiple]) {
background-position: 10px, 15px;
}

input[type="checkbox"],
input[type="radio"] {
vertical-align: middle;
position: relative;
width: min-content;
}
input[type="checkbox"] + label,
input[type="radio"] + label {
display: inline-block;
}
input[type="radio"] {
border-radius: 100%;
}
input[type="checkbox"]:checked,
input[type="radio"]:checked {
background-color: var(--accent);
}
input[type="checkbox"]:checked::after {

content: " ";
width: 0.18em;
height: 0.32em;
border-radius: 0;
position: absolute;
top: 0.05em;
left: 0.17em;
background-color: transparent;
border-right: solid var(--bg) 0.08em;
border-bottom: solid var(--bg) 0.08em;
font-size: 1.8em;
transform: rotate(45deg);
}
input[type="radio"]:checked::after {

content: " ";
width: 0.25em;
height: 0.25em;
border-radius: 100%;
position: absolute;
top: 0.125em;
background-color: var(--bg);
left: 0.125em;
font-size: 32px;
}

@media only screen and (max-width: 720px) {
textarea,
select,
input {
width: 100%;
}
}

input[type="color"] {
height: 2.5rem;
padding: 0.2rem;
}

input[type="file"] {
border: 0;
}

hr {
border: none;
height: 1px;
background: var(--border);
margin: 1rem auto;
}
mark {
padding: 2px 5px;
border-radius: var(--standard-border-radius);
background-color: var(--marked);
color: black;
}
img,
video {
max-width: 100%;
height: auto;
border-radius: var(--standard-border-radius);
}
figure {
margin: 0;
display: block;
overflow-x: auto;
}
figcaption {
text-align: center;
font-size: 0.9rem;
color: var(--text-light);
margin-bottom: 1rem;
}
blockquote {
margin-inline-start: 2rem;
margin-inline-end: 0;
margin-block: 2rem;
padding: 0.4rem 0.8rem;
border-inline-start: 0.35rem solid var(--accent);
color: var(--text-light);
font-style: italic;
}
cite {
font-size: 0.9rem;
color: var(--text-light);
font-style: normal;
}
dt {
color: var(--text-light);
}

code,
pre,
pre span,
kbd,
samp {
font-family: var(--mono-font);
color: var(--code);
}
kbd {
color: var(--preformatted);
border: 1px solid var(--preformatted);
border-bottom: 3px solid var(--preformatted);
border-radius: var(--standard-border-radius);
padding: 0.1rem 0.4rem;
}
pre {
padding: 1rem 1.4rem;
max-width: 100%;
overflow: auto;
color: var(--preformatted);
}

pre code {
color: var(--preformatted);
background: none;
margin: 0;
padding: 0;
}



progress {
width: 100%;
}
progress:indeterminate {
background-color: var(--accent-bg);
}
progress::-webkit-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent-bg);
}
progress::-webkit-progress-value {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
}
progress::-moz-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
transition-property: width;
transition-duration: 0.3s;
}
progress:indeterminate::-moz-progress-bar {
background-color: var(--accent-bg);
}
dialog {
max-width: 40rem;
margin: auto;
}
dialog::backdrop {
background-color: var(--bg);
opacity: 0.8;
}
@media only screen and (max-width: 720px) {
dialog {
max-width: 100%;
margin: auto 1em;
}
}

.notice {
background: var(--accent-bg);
border: 2px solid var(--border);
border-radius: 5px;
padding: 1.5rem;
margin: 2rem 0;
}

strong{
color:#d81b60;
}
em {
color:#e0467e; 
}
hr
{
border: 1px;
clear: both;
display: block;
width: 100%;
height: 1px;

background-color:#686868
}
</style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Your Digest for Friday, Dec 15, 2023 03:59 PM</h1>
</header>
<hr />
<ul>
<li>Adrenal adenoma is seen only in 20-30%.</li>
</ul>
<blockquote>
<p>&#39;Muscle weakness&#39; as a symptom is more common with adenomas.</p>
</blockquote>
<hr />
<pre><code>- Most specific rash is the *❗heliotrope* rash but it&#39;s present *only in a minority*.
- 20% of those with PM or DM have **anti tRNA synthetase antibodies** and are more likely to get *pulmonary interstitial fibrosis*, Raynaud&#39;s phenomenon, and &quot;*mechanic&#39;s hands* - roughening and cracking of skin&quot;.
</code></pre>
<hr />
<ul>
<li>Obligate <strong>intracellular</strong> <strong>protozoan</strong> parasite.</li>
</ul>
<ol>
<li>cat sheds <strong>oocysts</strong> with faeces which mature after about <strong>5 days in</strong> the environment.</li>
</ol>
<ul>
<li>Symptoms are may be flu like; about 15% develop #lymphadenopathy (<em>painless</em>) (usually <strong>head and neck</strong>) . Symptoms resolve <em>spontaneously</em> in a <strong>few weeks to months</strong>;</li>
</ul>
<h3 id="comparison-of-toxoplasmosis-with-cat-scratch-disease">Comparison of toxoplasmosis with cat-scratch disease</h3>
<table>
<thead>
<tr class="header">
<th>Toxoplasmosis</th>
<th>Cat Scartch</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Protozoa</td>
<td>Gram -ve bacteria</td>
</tr>
<tr class="even">
<td>head and neck lyphadenopathy</td>
<td>Regional lymphadenopathy</td>
</tr>
<tr class="odd">
<td>Non tender lymphadenopathy</td>
<td>Always tender</td>
</tr>
<tr class="even">
<td>No treatment needed</td>
<td>Usually no treatment needed</td>
</tr>
<tr class="odd">
<td>If needed, pyrimethamine</td>
<td>Azithromycin, TMP-SMX</td>
</tr>
</tbody>
</table>
<h4 id="cat-scratch-disease">Cat Scratch disease</h4>
<ul>
<li>Caused by Bartonella henselae</li>
<li>A common cause of <strong>chronic lymphadenopathy</strong> (several weeks)</li>
<li>A cause of PUO.</li>
<li>Initial innoculation site develops a papule which lasts 1 to 3 weeks.</li>
<li>Followed by lymphadenopathy of the draining nodes; single node involvment is common.</li>
<li><strong>Perinaud oculoglandular syndrome</strong> is a complication: Facial region lyphadenopathy and infection of conjuctiva, eye lid and adjacent skin.</li>
<li>Can also cause neuroretinitis and neurologic manifestations. (encephalopathy)</li>
<li><strong>Diagnosis</strong>:
<ul>
<li>Mainstay is the clinical picture.</li>
<li>Serology is unreliable;</li>
<li>Biopsy is not usually required by shows <em>Granulomas</em>. <em>Warthin-Starry stain is used to identify the bacterial</em></li>
<li>PCR on biopsy samples can be done.</li>
<li>Culture - fastidious organism; needs specific culture techniques -&gt; inform the microbiology team beforehand.</li>
</ul></li>
</ul>
<hr />
<h1 id="mixed-connective-tissue-disease-mctd">Mixed connective tissue disease (MCTD)</h1>
<blockquote>
<p>[!TIP] Mnemonic : SMS<br />
Overlap of SLE, Myositis and Scleroderma</p>
</blockquote>
<ul>
<li>AKA Sharp&#39;s syndrome.</li>
<li>Combines feature of <strong>SLE</strong>, <strong>Systemic Sclerosis</strong> and <strong>myositis</strong>.</li>
<li><strong>NOT the same as</strong> undifferentiated connective tissue disease.</li>
<li>1/3 undergo remission, 1/3 chronic symptoms, 1/3 severe systemic disease and premature death.</li>
<li><strong>Clinical features</strong> <a href="https://emedicine.medscape.com/article/335815-overview">Source</a>
<ul>
<li><strong>Raynaud&#39;s</strong> - <strong>usually the first symptom</strong></li>
<li>Arthritis / arthralgia</li>
<li>Oesophageal dysmotility</li>
<li>Lung Fibrosis + <em>pulmonary hypertension</em></li>
<li>Myositis</li>
<li>High level of anti-U1-RNP</li>
<li>presence of anti-snRNP</li>
<li>and dsDNA and anti-Scl70 (SLE and SSc) should be negative.</li>
</ul></li>
<li><strong>Treatment</strong>: Similar to that of SLE and SSc.
<ul>
<li>CCBs for Raynauds&#39;.</li>
<li>Endothelin receptor agonist / prostacyclin analogues for pulmonary hypertension.</li>
</ul></li>
</ul>
<h1 id="the-great-autoimmune-antibody-table">The Great Autoimmune antibody table</h1>
<p>List each disease and the autoantibodies which accompany it.</p>
<ul>
<li><p><strong>Mixed connective tissue disease</strong>:</p>
<ul>
<li><em>Defining Ab</em>: Anti U1RNP. (they can be + in SSc and SLE)</li>
<li>ANA +</li>
<li>anti ds-DNA -</li>
<li>Anti Scl70 - (the scleroderma antibodies)</li>
</ul></li>
<li><p><strong>SLE</strong></p>
<ul>
<li><em>Anti-dsDNA</em></li>
</ul></li>
<li><p><strong>Limited cutaneous Systemic Scleroris</strong>:</p>
<ul>
<li>anti-centromere antibodies</li>
</ul></li>
<li><p>Diffuse cutaneous SSc:</p>
<ul>
<li><em>anti-Scl70</em> (Topoisomerase 1)</li>
</ul></li>
<li><p>Antisynthetase sydnrome</p>
<ul>
<li>Anti tRNA synthetase</li>
</ul></li>
</ul>
<hr />
<blockquote>
<p>[!INFO] ⬇GFR -&gt; increases urate; conversely gout can impair renal function.<br />
Two main mechanisms : nephrolithiasis and chronic urate nephropathy;<br />
So management of gout with concurrent renal impairment is a clinical issue.</p>
</blockquote>
<blockquote>
<p>[!INFO] Main aspects of treatment are</p>
<ul>
<li><strong>Analgesia / acute relief</strong></li>
<li>Urare Lowering Therapy (<strong>ULT</strong>) as needed.
<ul>
<li>New guidelines advocate ULT for all patients after the very first episode.</li>
</ul></li>
<li>There are many medications to use if these fail.</li>
</ul>
</blockquote>
<h2 id="treatment-of-acute-flares">Treatment of acute flares:</h2>
<ul>
<li>NSAIDS, colchicine and systemic steroids are all effective.</li>
<li>So, choice is determined by contraindications.</li>
<li>Colchicine - alternative to NSAIDS. Inhibits neutrophil microtubules, thereby impairing neutrophil migration into sites of inflammation but it has <em>slower onset of action</em> and <strong>also contraindicated (UpToDate) (or⬇dose (BNF)) in renal impairment</strong>.</li>
<li>Corticosteroids - <em>oral</em> prednisolone or <em>IM</em> or <em>intra-articular depot</em> methylprednisolone.</li>
</ul>
<h4 id="colchicine">Colchicine</h4>
<ul>
<li>use with caution in combination with P450 <em>inhibitors</em>.</li>
<li><strong>GI side effects</strong> are the commonest.</li>
<li>Can cause <strong>neuromyopathy</strong> -&gt; numbness and weakness with chronic therapy.</li>
<li>First few episodes of gout are managed symptomatically as above. (new guidelines recomment ULT from first episode)
<ul>
<li><strong>Non purine analog</strong> that <em>inhibits xanthine oxidase</em>.</li>
<li><strong>Probenecid</strong> - avoid in renal impairment</li>
</ul></li>
<li><strong>Losartan</strong> -
<ul>
<li><strong>Anakinra</strong> - IL-1 inhibitor; very expensive.</li>
</ul></li>
</ul>
<blockquote>
<p>[!TIP] How to answer questions about best drug to use</p>
<ol>
<li>Identify the condition.</li>
<li>Find the most common first line treatment in the answers.</li>
<li>Look if the patient was pregnant.</li>
<li>Find in the PMH a reason u wouldn&#39;t choose this medication.</li>
<li>Find in the medication history any interactions like P450, bleeding.<br />
Common meds I found to raise a red flag : Sulfa, warfarin, Clari, Stations, Folic acid inhibitors like Trimeth./ Methotrex, Allopurino, Thiazide...<br />
--- Passmedicine Comment.</li>
</ol>
</blockquote>
<hr />
<h1 id="autoantibodies">Autoantibodies</h1>
<hr />
<p>|Extrahepatic manifestations|&quot;Serious Pirates Plundered Nine gold diamond chests&quot;|Arthritis, myalgia, Sjogrens, kerato. conj. sicca, Mooren corneal ulcer, porphyria cutanea tarda, lichen planus, asymptomatic mixed cryoglobulinaemia (Type II cgb), <em>membranoproliferative glomerulonephritis</em>|</p>
</body>
</html>
